Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre A, Bachet J, Boige V, Cayre A, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre A, Bachet J, Boige V, Cayre A, et al.
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • In 1971, one in 69 people was a cancer survivor (three million survivors). In 2014, that number grew to one in 22 people (14.5 million survivors).  
  • The 5-year survival rate for prostate cancer has increased from 67% to nearly 100% over the past 20 years.  
  • The increase in the stock of cancer drugs from 1975 to 1995 accounted for about 50 to 60 percent of the increase in age-adjusted survival rates in the first 6…  
  • Medical research that resulted in a 1/5 reduction in deaths from cancer would be worth $10 trillion to Americans-double the national debt.